In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
NIH STTR award
More News and Events
-
Tango Biosciences Celebrates 10 Years of Discovery
This year Tango Biosciences celebrates their ten-year anniversary, a milestone that resonates with scientific innovation and a sustained commitment to solving complex challenges in drug discovery and diagnostics. Visionary founders Dr. Brian Kay and Michael Scholle recently sat down to take a deep dive into the company’s incredible journey. They revealed an origin story that perfectly […]
-
Event
SLAS 2026
Visit Tango Biosciences at the 2026 SLAS International Conference & Exhibition! February 7-11, 2026 | Boston, MA Booth #1435 Plus, mark your calendar to join our Solutions Spotlight and poster presentations: Solutions Spotlight Presentation: Phage display in action: accelerating peptide, antibody, and molecular glue discovery through affinity, selectivity, and speed Wednesday, February 11 | 11:00am […]
-
NIH Awards New SBIR Grant
The National Institutes of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in July 2025. This award will support the application of Tango Biosciences’ proprietary Avidimer platform for the development of protein tools that enhance the discovery of proximity inducing modalities such as molecular glues. The Avidimers developed in this program will generate proof-of-concept […]